Autres langues Celldex Therapeutics, Inc.

Actions

CLDX

US15117B2025

Marché Fermé - Nasdaq Autres places de cotation 22:00:01 02/05/2024			Varia. 5j.	Varia. 1 janv.
40,93 ^USD	+4,02%		+12,88%	+3,20%

17/04	Celldex Therapeutics, Inc. annonce la fin du recrutement dans l'étude de phase 2 du barzolvolimab chez les patients atteints d'urticaire chronique inductible	CI
28/02	Celldex Therapeutics propose un placement d'actions ordinaires souscrites de 250 millions de dollars	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sector Update: Health Care Stocks Mixed Wednesday Afternoon	17/04
Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise	17/04
Celldex Therapeutics : Corporate Presentation	17/04
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	17/04
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	17/04
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	08/03
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares	06/03
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference	06/03
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	05/03
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares	05/03
Celldex Therapeutics Prices $400.4 Million Common Stock Offering	01/03
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock	01/03
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering	28/02
Celldex Therapeutics Announces Proposed Public Offering of Common Stock	28/02
Sector Update: Health Care Stocks Weaker Monday Afternoon	26/02
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates	26/02
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria	26/02
Sector Update: Health Care Stocks Mixed Premarket Monday	26/02
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell	26/02
Celldex: Q4 Earnings Snapshot	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Celldex Therapeutics, Inc.

Actions

CLDX

US15117B2025

Autres langues

Filtres